← Back to headlines
VERAXA Biotech Advances Cancer Program and Expands Patent Portfolio
VERAXA Biotech is making progress with its VXA-222 cancer program and simultaneously expanding its patent portfolio for next-generation therapies.
6 Aug, 16:27 — 6 Aug, 16:27
